Galectin Therapeutics (NASDAQ:GALT) Shares Cross Below Two Hundred Day Moving Average – Here’s What Happened

Posted by Francis Steltz on Nov 6th, 2026

Galectin Therapeutics Inc. (NASDAQ:GALT – Get Free Report) passed below its two hundred day moving average during trading on Thursday. The stock has a two hundred day moving average of $3.22 and traded as low as $2.91. Galectin Therapeutics shares last traded at $2.97, with a volume of 396,557 shares.

Analyst Ratings Changes

GALT has been the subject of a number of recent analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Galectin Therapeutics in a report on Monday, September 14th. Zacks Research raised shares of Galectin Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 11th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $11.00.

Read Our Latest Research Report on GALT

Galectin Therapeutics Stock Performance

The stock has a market capitalization of $195.60 million, a PE ratio of -6.91 and a beta of 0.53. The stock’s 50-day moving average price is $3.76 and its two-hundred day moving average price is $3.22.

Galectin Therapeutics (NASDAQ:GALT – Get Free Report) last announced its earnings results on Friday, August 14th. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.05). On average, analysts predict that Galectin Therapeutics Inc. will post -0.30 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Galectin Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the company. Argyle Capital Partners LLC bought a new stake in shares of Galectin Therapeutics in the 2nd quarter worth $62,000. Archer Investment Corp purchased a new stake in shares of Galectin Therapeutics during the 2nd quarter valued at about $81,000. Bank of America Corp DE raised its position in Galectin Therapeutics by 114.9% in the first quarter. Bank of America Corp DE now owns 53,862 shares of the company’s stock worth $150,000 after acquiring an additional 28,799 shares during the period. Hopwood Nicholas Hunter bought a new position in Galectin Therapeutics in the 2nd quarter worth $322,000. Finally, Bank of New York Mellon Corp bought a new position in shares of Galectin Therapeutics in the second quarter worth about $491,000. Institutional investors own 11.68% of the company’s stock.

Galectin Therapeutics Company Profile

(Get Free Report)

Galectin Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapies that target galectin-3, a protein associated with fibrosis, inflammation and immune regulation. The company’s research is aimed at treating serious chronic diseases in which galectin-3 may contribute to disease progression.

Its lead investigational product is belapectin, also known as GR-MD-02, a galectin-3 inhibitor being studied primarily for liver diseases, including nonalcoholic steatohepatitis (NASH), now commonly referred to as metabolic dysfunction-associated steatohepatitis (MASH), and related cirrhosis complications such as portal hypertension.